1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. News
  7. Summary
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mayne Pharma Group Limited Begins Distribution of Tacrolimus Ointment

01/11/2022 | 04:22pm EDT

Mayne Pharma Group Limited announced it has begun distribution of tacrolimus ointment, 0.1% in the United States. Tacrolimus ointment is a generic version of PROTOPIC®, indicated for the treatment of atopic dermatitis. According to IQVIA, the annual US market sales for tacrolimus ointment were USD 80 million for the twelve months ending November 20211. Mayne Pharma entered into a license and supply agreement with Sandoz AG to distribute tacrolimus ointment in non-retail channels.


© S&P Capital IQ 2022
All news about MAYNE PHARMA GROUP LIMITED
05/09Mayne pharma announced as recipient of $4.8m federal government grant
AQ
05/09Mayne Pharma Group Secures $3.4 Million Manufacturing Grant
MT
03/22Mayne Pharma Group Limited - NON-EXECUTIVE DIRECTOR APPOINTMENT
AQ
03/21MAYNE PHARMA : 22/03/2022 Non Executive Director Appointment
PU
03/21Ann Custin Accepts to Join the Board and Audit and Risk Committee of Mayne Pharma Group..
CI
03/20MAYNE PHARMA GROUP LIMITED(ASX : MYX) added to S&P/ASX Emerging Companies Index
CI
02/28Mayne pharma reports 1hfy22 results
AQ
02/25Mayne Pharma Group Narrows Loss in Six Monts to December 2021
MT
02/24TRANSCRIPT : Mayne Pharma Group Limited, H1 2022 Earnings Call, Feb 24, 2022
CI
02/24MAYNE PHARMA : 2022 Half Year Investor Presentation
PU
More news
Financials
Sales 2022 403 M 289 M 289 M
Net income 2022 -75,3 M -53,9 M -53,9 M
Net Debt 2022 271 M 194 M 194 M
P/E ratio 2022 -6,28x
Yield 2022 -
Capitalization 521 M 372 M 372 M
EV / Sales 2022 1,96x
EV / Sales 2023 1,71x
Nbr of Employees 967
Free-Float 77,3%
Chart MAYNE PHARMA GROUP LIMITED
Duration : Period :
Mayne Pharma Group Limited Technical Analysis Chart | MYX | AU000000MYX0 | MarketScreener
Technical analysis trends MAYNE PHARMA GROUP LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 0,30 AUD
Average target price 0,36 AUD
Spread / Average Target 21,2%
EPS Revisions
Managers and Directors
Scott Richards Chief Executive Officer, MD & Executive Director
Peter Paltoglou Chief Financial Officer
Frank C. Condella Chairman
Gerard G. Nahum Chief Medical Officer
Keith Moore Vice President-Research & Development